Carvedilol (Coreg, Coreg CR) and Black patients
Brand names: Coreg, Coreg CR
What Carvedilol does
Carvedilol is a non-selective beta blocker that also blocks alpha-1 receptors, giving it vasodilating properties that most other beta blockers lack. Those combined effects are why it is one of the three guideline-preferred beta blockers for heart failure with reduced ejection fraction — along with metoprolol succinate and bisoprolol.
What the evidence says for Black patients
Carvedilol has the most favorable evidence base for Black patients with heart failure among beta blockers. The COPERNICUS trial (Packer et al., NEJM 2001;344:1651–8) and the US Carvedilol Heart Failure Program established mortality and hospitalization benefits, with a subgroup analysis showing consistent effects in Black participants. The US Carvedilol trials enrolled proportionally more Black participants than most contemporary HF trials, strengthening the evidence.
After the BEST trial of bucindolol suggested a race-treatment interaction for beta blockers in HFrEF (Eichhorn et al., NEJM 2001;344:1659–67), carvedilol was looked at with more scrutiny — and came through with benefit consistent across racial groups.
For hypertension without a compelling indication, carvedilol is not first-line in Black adults (as with other beta blockers). But when hypertension coexists with HFrEF, a recent MI, or angina, carvedilol is a strong choice.
Common alternatives
Metoprolol succinate is the main alternative for HFrEF; head-to-head, both are acceptable and the choice often comes down to blood pressure (carvedilol lowers BP more), history of asthma (metoprolol is more cardioselective), and tolerance. For Black HFrEF patients, guidelines recommend adding hydralazine plus isosorbide dinitrate (BiDil) based on the A-HeFT trial (Taylor et al., NEJM 2004;351:2049–57).
Side effects
- Dizziness, orthostatic hypotension (from alpha blockade)
- Fatigue
- Bradycardia
- Bronchospasm — avoid in asthma
- Weight gain
- Sexual dysfunction
Factors that affect adherence
Carvedilol must be taken with food to slow absorption and avoid orthostatic dizziness. Starting low (3.125 mg BID) and up-titrating every 2 weeks reduces symptomatic hypotension. Generic immediate-release carvedilol is inexpensive; the controlled-release form is costlier and usually not necessary.
Questions to ask your doctor
Bring this list to your next appointment.
- Am I on the right dose, and when will we uptitrate?
- If I also have asthma, is this safe?
- If I have Black heart failure, should I also be on BiDil?
- What do I do if I feel dizzy when standing?
References
- Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). NEJM. 2001;344:1651–1658.
- Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure (US Carvedilol Heart Failure Study Group). NEJM. 1996;334:1349–1355.
- Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure (A-HeFT). NEJM. 2004;351:2049–2057. PMID 15533851.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Heart Failure Guideline. Circulation. 2022;145:e895–e1032.
- U.S. Food and Drug Administration. Coreg (carvedilol) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038,020712s024lbl.pdf
Medical disclaimer
This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.
Read our editorial standards for how we source, review, and update these pages.